VVD-133214, an allosteric inhibitor of WRN helicase with promising efficacy in MSI-H cancer models
May 14, 2024
Researchers from Vividion Therapeutics Inc. and partner Roche Holdings AG have published the discovery and preclinical characterization of the novel covalent allosteric inhibitor of WRN, VVD-133214 (RO-7589831).
